Treatment-Emergent Isolated EGFR C797S Mutation Following First-Line Osimertinib-Based Combination Therapy: A Case Report and Literature Review
{{output}}
Osimertinib is the standard first-line treatment for EGFR-mutated non-small cell lung cancer (NSCLC), although acquired resistance remains inevitable. The EGFR C797S mutation is a recognized on-target resistance mechanism; however, the T790M-negative/C797S-onl... ...
